<?xml version="1.0" encoding="UTF-8"?>
<GaPExchange xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:noNamespaceSchemaLocation="./dbGaPEx2.1.5.xsd">

<MetaVariables>
	<Submitter/>
	<Method/>
</MetaVariables>
<MetaLinks/>

<Projects>
	<Project/>
</Projects>

<Studies>

<Study source="dbGaP" accession="phs001231.v1.p1" parentStudy="phs001231.v1.p1" createDate="2016-10-20" modDate="2017-04-21">

<Configuration>
	<Data_Provider><![CDATA[
		<table border="1">
		<tr><th>Title</th><th>Name</th><th>Institute</th></tr>
		<tr><td>Principal Investigators</td><td>Leslie Thompson, PhD</td><td>University of California, Irvine, CA, USA</td></tr>
		<tr><td>Principal Investigators</td><td>Clive Svendsen, PhD</td><td>Regenerative Medicine Institute, Cedars Sinai, Los Angeles, CA, USA</td></tr>
		<tr><td>Principal Investigators</td><td>Steve Finkbeiner, MD, PhD</td><td>Gladstone Institutes, San Francisco, CA, USA</td></tr>
		<tr><td>Principal Investigators</td><td>Ernest Fraenkel, PhD</td><td>Massachusetts Institute of Technology, Cambridge, MA, USA</td></tr>
		<tr><td>Principal Investigators</td><td>Jeff Rothstein, MD, PhD</td><td>Johns Hopkins School of Medicine, Baltimore, MD, USA</td></tr>
		</table>
	]]></Data_Provider>
	<StudyNameEntrez>NeuroLINCS</StudyNameEntrez>
	<StudyNameReportPage>The Library of Integrated Network-Based Cellular Signatures (LINCS) - NeuroLINCS</StudyNameReportPage>
	<StudyTypes>
		<StudyType>Case-Control</StudyType>
	</StudyTypes>
	<Description><![CDATA[
<p>The NeuroLINCS Center is part of the NIH Common Fund&#39;s Library of Integrated Network-based Cellular Signatures (LINCS) program, which aims to characterize how a variety of human cells, tissues and the entire organism respond to perturbations by drugs and other molecular factors.</p> <p>As Part of the LINCS program, the NeuroLINCS study concentrates on human brain cells, which are far less understood than other cells in the body. Our initial focus is to produce diseased motor neurons from patients by utilizing high-quality induced pluripotent stem cell (iPSC) lines from Amyotrophic Lateral Sclerosis (ALS) and Spinal Muscular Atrophy (SMA) patients in addition to unaffected normal healthy controls. Using state-of-the-art OMICS methods (genomics, epigenomics, transcriptomics, and proteomics), we intend to create a wealth of cellular data that is patient-specific in the context of their baseline genetic perturbations and in the presence of other genetic and environmental perturbagens (e.g. endoplasmic reticulum stress). The primary data will be used to build cell signatures that convey the key features that distinguish the state of a cell and determine its behavior. Ultimately, the analysis of these datasets will lead to the identification of a network of unique signatures relevant to each of these motor neuron diseases. The datasets represented in this study are generated from assays interrogating RNA expression (RNA-seq), chromatin accessibility (ATAC-seq) and whole genome sequencing. </p>]]>
	</Description>
	<StudyInEx><![CDATA[
<p>Case samples were included if clinical history description included ALS (C9, SOD1 or sporadic) or SMA (SMN 1 deletion) diagnosis. Control cohort had no history of ALS or SMA phenotype.</p>]]>
	</StudyInEx>
	<StudyProjects>
		<Project/>
	</StudyProjects>
	<Publications>
		<Publication>
			<Pubmed pmid="27146274"/>
		</Publication>
		<Publication>
			<Pubmed pmid="27116041"/>
		</Publication>
		<Publication>
			<Pubmed pmid="27150398"/>
		</Publication>
		<Publication>
			<Pubmed pmid="26998601"/>
		</Publication>
		<Publication>
			<Pubmed pmid="26308891"/>
		</Publication>
		<Publication>
			<Pubmed pmid="27428653"/>
		</Publication>
		<Publication>
			<Pubmed pmid="27479327"/>
		</Publication>
	</Publications>
	<Diseases>
		<Disease vocab_source="MESH" vocab_term="Amyotrophic Lateral Sclerosis"/>
		<Disease vocab_source="MESH" vocab_term="Muscular Atrophy, Spinal"/>
		<Disease vocab_source="MESH" vocab_term="Spinal Muscular Atrophies of Childhood"/>
	</Diseases>
	<Attributions>
		<Header title="Principal Investigators">
			<AttName>Leslie Thompson, PhD</AttName>
			<Institution>University of California, Irvine, CA, USA</Institution>
		</Header>
		<Header title="Principal Investigators">
			<AttName>Clive Svendsen, PhD</AttName>
			<Institution>Regenerative Medicine Institute, Cedars Sinai, Los Angeles, CA, USA</Institution>
		</Header>
		<Header title="Principal Investigators">
			<AttName>Steve Finkbeiner, MD, PhD</AttName>
			<Institution>Gladstone Institutes, San Francisco, CA, USA</Institution>
		</Header>
		<Header title="Principal Investigators">
			<AttName>Ernest Fraenkel, PhD</AttName>
			<Institution>Massachusetts Institute of Technology, Cambridge, MA, USA</Institution>
		</Header>
		<Header title="Principal Investigators">
			<AttName>Jeff Rothstein, MD, PhD</AttName>
			<Institution>Johns Hopkins School of Medicine, Baltimore, MD, USA</Institution>
		</Header>
		<Header title="Co-Investigator">
			<AttName>Jennifer Van Eyk, PhD</AttName>
			<Institution>Women&#39;s Heart Center, Cedars Sinai, Los Angeles, CA, USA</Institution>
		</Header>
		<Header title="Funding Source">
			<AttName>NS091046 (NIH U54)</AttName>
			<Institution>National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health, Bethesda, MD, USA</Institution>
		</Header>
	</Attributions>
	<DisplayPublicSummary>yes</DisplayPublicSummary>
	<StudyURLs>
		<Url name="NeuroLINCS" url="http://www.lincsproject.org/LINCS/centers/data-and-signature-generating-centers/neurolincs"/>
		<Url name="LINCS" url="http://www.lincsproject.org/"/>
		<Url name="Chorus" url="https://chorusproject.org/pages/index.html"/>
	</StudyURLs>
	<ConsentGroups>
		<ConsentGroup groupNum="1" shortName="GRU" longName="General Research Use"/>
		<ConsentGroup groupNum="2" shortName="DS-NNMC" longName="Disease-Specific (neurologic and neuromuscular conditions)"/>
	</ConsentGroups>
</Configuration>

  <AuthorizedAccess>
    <DacInfo ssDacId="0">
      <DacName>NINDS</DacName>
      <DacFullName>National Institute of Neurological Disorders and Stroke</DacFullName>
      <DacEmail>0</DacEmail>
      <DacPhone></DacPhone>
      <DacUrl></DacUrl>
    </DacInfo>
    <Policy Policy_ID="phs001231.v1.p1_policy" ref_ssDacId="0">
      <DisplayResearchStatement>yes</DisplayResearchStatement>
      <DisplayPublicSummary>yes</DisplayPublicSummary>
      <EmbargoLength>0</EmbargoLength>
      <YearsUntilRenewal>1</YearsUntilRenewal>
      <WeeksCancelRequest>8</WeeksCancelRequest>
      <PdfSupplementReqired>no</PdfSupplementReqired>
      <AcknowledgementText>
        <para>
          http://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=DUC&amp;view_pdf&amp;stacc=phs001231.v1.p1
        </para>
      </AcknowledgementText>
      <DocumentSet>
        <DataUseCertificate Label="Data Use Certificate" FilePath="https://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=DUC&amp;view_pdf&amp;stacc=phs001231.v1.p1" FileName=""/>
      </DocumentSet>
    </Policy>
    <ConsentGroups>
      <ParticipantSet groupNum-REF="1">
        <ConsentName>General Research Use</ConsentName>
        <ConsentAbbrev>GRU</ConsentAbbrev>
        <UseLimitation>Use of the data is limited only by the terms of the model Data Use Certification.</UseLimitation>
        <IrbRequired>No</IrbRequired>
      </ParticipantSet>
      <ParticipantSet groupNum-REF="2">
        <ConsentName>Disease-Specific (neurologic and neuromuscular conditions)</ConsentName>
        <ConsentAbbrev>DS-NNMC</ConsentAbbrev>
        <UseLimitation>Use of the data must be related to neurologic and neuromuscular conditions.</UseLimitation>
        <IrbRequired>No</IrbRequired>
      </ParticipantSet>
    </ConsentGroups>
  </AuthorizedAccess>


</Study>

</Studies>

</GaPExchange>
